BioNxt的癌症药物BNX-21在第二阶段试验中使60%的病人的肿瘤减缩,促使计划寻求林业发展局批准。 BioNxt's cancer drug BNX-21 shrank tumors in 60% of patients in a Phase 2 trial, prompting plans to seek FDA approval.

BioNxt是一家生物技术公司,今天宣布其实验性癌症治疗BNX-21在第二阶段临床试验中取得了可喜成果,60%的参与者患有肿瘤萎缩。 BioNxt, a biotechnology company, announced today that its experimental cancer treatment, BNX-21, showed promising results in a Phase 2 clinical trial, with 60% of participants experiencing tumor shrinkage. 该公司计划向FDA提交数据以获得加速批准. The company plans to submit data to the FDA for accelerated approval. 调查结果在波士顿的一次医疗会议上提出,正在等待独立审查。 Results were presented at a medical conference in Boston and are pending independent review.